Sobi to host a Capital Markets Day on 18 February 2026

Swedish Orphan Biovitrum (Sobi) will hold an in-person Capital Markets Day in Stockholm on 18 February 2026 (13:00–16:00 CET) with a live webcast; CEO Guido Oelkers and the management team will present strategy (Ambition 2030), pipeline and physician-led therapeutic area sessions including disease deep dives on severe gout, sHTG and sepsis. The event is positioned to update investors on pipeline progress, innovation and shareholder value delivery from management (CFO Henrik Stenqvist attached), with background metrics noting 2025 revenue of SEK 28 billion and ~1,900 employees; the day could influence forward guidance or investor sentiment if material new guidance or clinical updates are disclosed.

Analysis

Market structure: Sobi’s CMD is a classic event-catalyst for re-pricing a mid-cap rare-disease franchise (STO:SOBI). Clear Ambition 2030 targets or concrete launch/timing updates for gout and sHTG could increase pricing power in specialty channels and justify a 10–20% re-rating for realistically achievable CAGR >10% to 2030; lack of detail or conservative guidance could compress multiples by 5–10% as investors re-assess growth duration.

Risk assessment: Tail risks include clinical readouts or regulatory setbacks revealed or clarified at CMD (low-probability, high-impact), material dependence on 2–3 key assets and payer negotiations in US/EU, and SEK FX moves affecting reported SEK28bn revenue guidance; expect elevated event volatility in the ±3 trading days window and persistent repricing over 1–6 months if pipeline visibility doesn’t improve.

Trade implications: Event-driven strategies dominate — buy-side should size directional exposure modestly (1–3% capital) with explicit option hedges; implied volatility will rise pre-CMD so prefer defined-risk structures (call spreads, put-protective collars) or short-dated straddles only if funding edge exists. Cross-asset: monitor Swedish sovereign spreads (modest), SEK/EUR moves (SEK may strengthen on positive news), and credit of small biotech suppliers if M&A talk surfaces.

Contrarian angle: Consensus likely expects positive messaging; the miss is under-delivery on quantifiable KPIs (conservative Ambition 2030 milestones), which historically causes outsized drawdowns in specialty biotechs. If no hard milestone dates or commercial metrics are given, that’s the signal to underweight; conversely, a small feasibility win (specific payer deals or Phase 3 start) could be underappreciated and drive a >15% bounce.

Key Decisions for Investors

• Establish a 2% long position in Sobi (STO:SOBI) 5–10 trading days before the 18‑Feb‑2026 CMD to capture pre-event positioning; simultaneously buy 3‑month 10% OTM puts sized at 25% notional of the equity position as downside protection against a negative guidance/clinical surprise.
• If CMD delivers explicit Ambition 2030 KPIs (e.g., target revenue CAGR >10% or ≥2 new late‑stage programs with timelines), scale to 5% position within 1 week; if management lowers near‑term guidance or gives no launch/timing detail, reduce exposure to 0.5% and buy 3‑month 15% OTM puts or short 1–2% via CFD within 48 hours.
• Execute a relative-value pair: long STO:SOBI vs short HZNP (NASDAQ:HZNP) 1:1 notional (size 1–2% net) for 3 months to play potential European commercial share gains in gout/rare disease; unwind if SOBI underperforms HZNP by >8% in 30 days or after major trial readouts.
• If seeking pure volatility play, buy a 3‑month ATM straddle on STO:SOBI sized to 0.5–1% capital no earlier than 7 trading days pre‑CMD; if IV runs up >30% vs 90‑day average, switch to a long 1×2 call spread to cap cost.